Brittany Cote

Articles

Brahmer Highlights Practice-Changing Data in HER2-Mutated NSCLC

July 3rd 2020

Julie R. Brahmer, MD, discusses the details of the DESTINY-Lung01 trial, as well as remaining questions that could be answered with further research.

Efficacy With Entrectinib in NTRK+ GI Cancers Indicates a Need for More Molecular Testing

July 1st 2020

Manish R. Patel, DO, further discusses next steps for entrectinib, as well as the need for genetic testing to identify uncommon gene rearrangements in GI malignancies.

Expert Shares Efforts to Expand Use of CAR T-Cell Therapy to Solid Tumors

June 30th 2020

Natalie Sophia Grover, MD, discusses ongoing research with CAR T-cell therapy in hematologic malignancies, efforts examining the potential for this approach in solid tumors, and future directions and challenges with this modality.

Fakih Fleshes Out Perceptions on Pembrolizumab Approval in TMB-High Solid Tumors

June 30th 2020

Marwan G. Fakih, MD, discusses the June 2020 FDA approval of pembrolizumab for use in select patients with unresectable or metastatic solid tumors that are tumor mutational burden–high provides a potentially life-saving option to those who have exhausted all other available therapies.

Randall Issues Call for Multidisciplinary Management in Giant Cell Tumor of Bone

June 30th 2020

R. Lor Randall, MD, FACS, discusses the need for multidisciplinary collaboration in GCTB, challenges faced in the space, and directions for future research efforts.

Wang Weighs in on Promising Pharmacological Profile of KTE-X19 in High- and Low-Risk MCL

June 30th 2020

Michael Wang, MD, further discusses data regarding the pharmacological profile of KTE-X19, the significance of these findings, and the next steps for this research.

Belantamab Mafodotin Induces Responses in Relapsed/Refractory Myeloma, But Calls for Multidisciplinary Approach

June 29th 2020

Sagar Lonial, MD, FACP, discusses the updated data from DREAMM-2 with belantamab mafodotin, associated toxicities to be aware of, and future directions for research.

Nivolumab/Ipilimumab Combo Shows Promise in Metaplastic Breast Cancer

June 26th 2020

Sylvia Adams, MD, discusses the cohort 36 findings of the DART trial in metaplastic breast cancer and the evolution of immunotherapy, specifically in this rare breast cancer subtype.

Berdeja Projects Promising Future for JNJ-4528 in Relapsed/Refractory Myeloma

June 24th 2020

Jesus G. Berdeja, MD, further discusses other exciting trials in multiple myeloma and CAR T therapy being presented at the 2020 ASCO Virtual Scientific Program.

Tucatinib Combo Slated as New Third-Line Standard in HER2+ Breast Cancer With CNS Metastases

June 17th 2020

Nancy U. Lin, MD, discusses the updated data from the HER2CLIMB trial and underscored the need for future clinical trials that include patients with brain metastases to help fill the unmet need in the HER2-positive space.

Alpha-TEA and Concurrent Trastuzumab Under Exploration in Refractory HER2+ Breast Cancer

June 17th 2020

William R. Gwin III, MD, discusses the ongoing trial examining this novel combination and provided insight into the next steps for this research.

Cirmtuzumab Plus Ibrutinib Shows Activity and Tolerability in MCL and CLL

June 16th 2020

Hun Ju Lee, MD, discusses the interim results of a study examining cirmtuzumab plus ibrutinib and the next steps with this research in mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.

Maintenance Rituximab Improves Survival in Older Patients With MCL, But More Work Needed

June 16th 2020

Reem Karmali, MD, discusses survival outcomes in older patients with MCL with maintenance rituximab and highlights other ongoing MCL research efforts to optimize maintenance strategies in this patient population.

Frontline 4-Drug Atezolizumab Regimen Shows Tolerability and Minimal Treatment Burden in NSCLC

June 11th 2020

The 4-drug ABCP regimen improved survival while maintaining good health-related quality of life in patients with nonsquamous non–small cell lung cancer, according to patient-reported outcomes from the phase 3 IMpower150 trial.

Nivolumab/Ipilimumab Induction Therapy Boosts Responses and Prolongs PFS in Epithelial Ovarian Cancer

June 10th 2020

The combination of nivolumab plus ipilimumab was found to induce a superior response rate and longer progression-free survival compared with nivolumab alone in patients with persistent or recurrent epithelial ovarian cancer.

Philip Highlights Promise of Devimistat in Pancreatic Cancer

June 9th 2020

Philip A. Philip, MD, PhD, FRCP, discusses challenges in pancreatic cancer and the emergence of devimistat in the treatment paradigm.

Philip Highlights Promise of Devimistat in Pancreatic Cancer

June 9th 2020

Philip A. Philip, MD, PhD, FRCP, discusses challenges in pancreatic cancer and the emergence of devimistat in the treatment paradigm.

Pal Previews Promise of Cabozantinib Plus Atezolizumab in Heavily Pretreated Urothelial Cancer

June 9th 2020

Sumanta K. Pal, MD, discusses the clinical implications of the COSMIC-021 trial and highlights other exciting research efforts being made in genitourinary cancers.

Pal Previews Promise of Cabozantinib Plus Atezolizumab in Heavily Pretreated Urothelial Cancer

June 9th 2020

Sumanta K. Pal, MD, discusses the clinical implications of the COSMIC-021 trial and highlights other exciting research efforts being made in genitourinary cancers.

Siena Showcases Trastuzumab Deruxtecan Activity in HER2-Expressing mCRC

June 9th 2020

Salvatore Siena, MD, further discusses the DESTINY-CRC01 trial with trastuzumab deruxtecan and projects the impact of these findings on patients with HER2-expressing metastatic CRC.